XML 22 R10.htm IDEA: XBRL DOCUMENT
v3.19.1

Inventory | 3 Months Ended
--- | ---
Mar. 31, 2019
Inventory Disclosure [Abstract] |
Inventory |
(4) | Inventory
The Company capitalizes its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories as of March 31, 2019 and December 31, 2018 consist of the following:
In thousands |  | March 31, 2019 |  |  | December 31, 2018 |
Raw materials |  | $ | 7,941 |  |  | $ | 14,142 |
Work in process |  |  | 8,653 |  |  |  | 8,590 |
Finished goods |  |  | 41,473 |  |  |  | 35,357 |
Total inventory, gross |  |  | 58,067 |  |  |  | 58,089 |
Inventory cost adjustment |  |  | (158 | ) |  |  | (287 | )
Inventory |  | $ | 57,909 |  |  | $ | 57,802 |

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI http://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration